O. Berzoy

Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study

Nadia Harbeck, Priya Rastogi, Miguel Martín, Sara M. Tolaney et autres

BACKGROUND: Adjuvant abemaciclib combined with endocrine therapy (ET) previously demonstrated clinically meaningful improvement in invasive disease-free survival (IDFS) and distant relapse-free survival (DRFS) in hormone receptor-positive, human epidermal growth factor receptor 2-negative, node-positive, high-risk early breast cancer at the second interim analysis, …

ch, de, us, es, cn, tw, ru, pl, br, dk, jp, it, at, kr, gb (code pays fourni par la source)

Phase 3 efficacy and safety trial of proposed pegfilgrastim biosimilar MYL-1401H vs EU-Neulasta ® in the prophylactic treatment of chemotherapy-induced neutropenia

Cornelius F. Waller, Christopher Blakeley, Eduardo J. Pennella, Miguel H. Bronchud et autres

Phase 3 efficacy and safety trial of proposed pegfilgrastim biosimilar MYL-1401H vs EU-neulasta® in the prophylaxis of chemotherapy-induced neutropenia

Cornelius F. Waller, Christopher Blakeley, Eduardo J. Pennella, Miguel H. Bronchud et autres

de, us, es, ua, bg, hu, gb, in (code pays fourni par la source)